Loading market dashboard
ARS Pharmaceuticals, Inc.
SPRYHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
ARS Pharmaceuticals is now focused on scaling Neffy. This is their needle-free epinephrine spray for severe allergic reactions, and it's also core to my bull case on SPRY. Recently, we've seen SPRY double down on CVS Caremark, Medicaid, retail affordability, and a larger sales force to improve Neffy's access by 2H2026. Neffy is already generating commercial revenue, and the next test for my bull case is whether repeat sales grow as access improves.
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
ARS Pharmaceuticals NASDAQ: SPRY reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for neffy, its needle-free epinephrine treatment for allergic reactions including anaphylaxis.
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.35 per share a year ago.
Q1 2026 total revenue of $22.7 million including neffy ® (epinephrine nasal spray) U.S. net product revenue of $17.5 million
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) will release earnings for its first quarter before the opening bell on Friday, May 15.
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe allergic reactions that can lead to anaphylaxis, today announced the appointment of Donn Casale as President, effective June 1, 2026. Richard Lowenthal will continue to lead ARS Pharma as Chief Executive Officer.
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Friday, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2026 financial results and business highlights.
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ARS Pharmaceuticals, Inc. (SPRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
neffy offers a new delivery method for epinephrine in Canada for adults and children ( > 30 kg) living with severe allergic reactions
Children were previously required to weigh ≥33 lbs. and
Bamco Inc. NY grew its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by 3,071.3% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,268,532 shares of the company's stock after acquiring an additional 1,228,532 shares during the period. Bamco Inc. NY owned about
ARS Pharmaceuticals, Inc. maintains a Hold rating as neffy's commercial uptake remains slow despite FDA approval and a robust marketing push. SPRY reported 2025 revenues of $84.3m, a net loss of $171.3m, and plans to sustain high SG&A spending to accelerate U.S. market share. Management offers no 2026 revenue guidance, raising concerns about breakeven prospects and ongoing competition from established and emerging epinephrine products.
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.42 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.52 per share a year ago.
neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even Conference call to be held today, March 9, 2026, at 5:30 a.m. PT / 8:30 a.m.
